Geron Corp (OQ:GERN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 919 East Hillsdale Boulevard, Suite 250
FOSTER CITY CA 94404
Tel: N/A
Website: https://www.geron.com
IR: See website
<
Key People
John A. Scarlett
Chairman of the Board, President, Chief Executive Officer
Michelle Robertson
Chief Financial Officer, Executive Vice President, Treasurer
Andrew J. Grethlein
Executive Vice President, Chief Operating Officer
Stephen N. Rosenfield
Executive Vice President, Corporate Secretary, Chief Legal Officer
Faye Feller
Executive Vice President, Chief Medical Officer
Anil Kapur
Executive Vice President, Corporate Strategy and Chief Commercial Officer
Melissa A. Kelly Behrs
Executive Vice President - Business Operations, and Chief Alliance Officer
Edward Koval
Executive Vice President, Chief Business Officer
 
Business Overview
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Financial Overview
For the fiscal year ended 31 December 2023, Geron Corp revenues decreased 60% to $237K. Net loss increased 30% to $184.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Development of Therapeutical products segment loss increase of 40% to $193.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.37 to -$0.32.
Employees: 141 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,691M as of Dec 31, 2023
Annual revenue (TTM): $0.24M as of Dec 31, 2023
EBITDA (TTM): -$193.50M as of Dec 31, 2023
Net annual income (TTM): -$184.13M as of Dec 31, 2023
Free cash flow (TTM): -$168.57M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 586,912,213 as of Mar 21, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.